Synergy Pharmaceuticals Up 55% on Trulance Progress in Canada
18 12월 2018 - 5:43AM
Dow Jones News
By Josh Beckerman
Shares of Synergy Pharmaceuticals Inc. (SGYP), which filed for
bankruptcy last week, recently traded up 55% to 12 cents as the
company's flagship product Trulance was accepted for review by
Health Canada.
Cipher Pharmaceuticals Inc. (CPH.T) bought Canadian rights to
the constipation drug in Februrary.
Synergy filed for chapter 11 on Dec. 12 with a plan to sell its
assets to Bausch Health Companies Inc. (BHC) for about $200 million
in cash.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
December 17, 2018 15:28 ET (20:28 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
Synergy Pharmaceuticals, Inc. (나스닥)의 실시간 뉴스: 최근 기사 0
More Synergy Pharmaceuticals, Inc. News Articles